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Policy Forum
This is the third of three articles in the November 
2007 issue on developing new drug treatments for 
tuberculosis.
The Pressing Need for MDR-TB 
Clinical Trials
Drug-resistant strains of Mycobacterium
tuberculosis may account for 10% of 
the 8 million new cases of tuberculosis 
(TB) that occur annually. Systematic 
surveys have been undertaken in 
at least 90 countries. Drug-resistant 
isolates were found in every site, 
and multidrug-resistant tuberculosis 
(MDR-TB; resistant to at least isoniazid 
and rifampin) in all but eight [1]. 
Extensively drug-resistant tuberculosis 
(XDR-TB)—disease caused by MDR 
strains that are also resistant to at 
least one ﬂuoroquinolone and one or 
more injectable agents [2]—has been 
reported in at least 37 countries, with 
very poor treatment outcomes [3–5]. 
Increasing concern about resistance 
has redoubled interest in strategies to 
control drug-resistant TB, especially in 
settings of high HIV prevalence [6].
There is, therefore, increased 
urgency for clinical trials that will 
identify safe and effective regimens 
for patients who have no treatment 
options. Furthermore, although the 
feasibility and cost-effectiveness of 
treating patients with MDR-TB in 
resource-constrained countries is 
well established [7–13], outcomes 
of MDR-TB treatment remain 
suboptimal. MDR-TB can be lethal; 
5%–20% of HIV-uninfected patients 
[7,9–11,14] and 66% of HIV-infected 
patients die during treatment [15]. 
MDR-TB treatment lasts between 18 
and 24 months, and adverse events 
are common [16]. As a result, the 
combined frequency of cure and 
completion often remains below 
50% [7,17,18]. Even when therapy 
is designed with access to the full 
complement of antituberculosis agents 
presently available, outcomes rarely 
approach the target for TB treatment 
success (cure among at least 85% of 
patients initiating therapy) [14,19]. 
The long duration and toxicity of 
current MDR-TB regimens will impede 
achievement of the goal of treating 
nearly 1.6 million MDR-TB patients 
by 2015, set out in the Global Plan to 
Stop TB [20]. In addition, the poor 
outcomes of current regimens mean 
that many of those treated will develop 
chronic, highly resistant forms of TB 
that have a high mortality rate and can 
be transmitted to others.
The Past
The history of the development of 
current, short-course standardized 
treatment for drug-susceptible TB is 
instructive for developing regimens 
to treat MDR-TB. Identiﬁed through 
a series of randomized clinical trials, 
the short-course approach offered 
dramatic beneﬁts over earlier 
standards of care—treatment duration 
decreased from 24 to six months 
while outcomes improved [21]. In 
contrast, guidelines for management 
of MDR-TB [22] are based on expert 
opinion and results of cohort and case 
series analyses, since no large-scale 
randomized trials of treatment have 
been conducted.
As in the case of drug-susceptible 
TB, randomized controlled trials 
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Summary Points
The time is now right for randomized 
trials of MDR-TB:
u The burden of multidrug-resistant 
tuberculosis (MDR-TB) is growing, and 
the standard-of-care treatment is long, 
toxic, and frequently unsuccessful.
u The need for additional research 
is clearly illustrated by suboptimal 
treatment outcomes and limited 
estimates of the burden of MDR-TB 
and extensively drug-resistant TB.
u The expansion of MDR-TB treatment 
programs provides the settings in 
which trials can be implemented.
u For the ﬁrst time in 30 years, several 
new drug classes that hold promise 
for MDR-TB treatment are under 
development; these new agents 
should be evaluated in parallel for 
drug-resistant and drug-susceptible 
TB.
u Concerns about MDR-TB can help 
mobilize additional funding for TB 
drug development, while clinical trials 
for MDR-TB will likely allow accelerated 
regulatory approval for new agents.PLoS Medicine  |  www.plosmedicine.org 1731 November 2007  |  Volume 4  |  Issue 11  |  e292
would provide a strong evidence base 
for developing treatment regimens 
for MDR-TB using speciﬁc drug 
combinations and durations of therapy 
(of injectable and entire regimen). 
The global expansion of treatment 
for drug-resistant disease would thus 
be improved. Box 1 provides an 
example of the consequences of not 
subjecting to controlled clinical trials 
a new class of agents with documented 
antituberculosis activity.
Randomized trials of MDR-TB 
treatment have been long considered 
impossible for three reasons. First, the 
political will to improve treatment for 
MDR-TB has been lacking, in part due 
to perceptions that the disease has 
limited epidemiologic importance (i.e., 
few cases and poor ﬁtness of resistant 
organisms). Second, patients with 
MDR-TB show great variability in the 
extent of disease and degree of known 
intolerance to antituberculosis agents; 
their infecting isolates, moreover, vary 
in the degree of drug resistance. These 
differences were thought to preclude 
the implementation of classical clinical 
trials, which compare the efﬁcacy of 
ﬁxed regimens. Finally, many thought 
that, due to the relative dearth of 
patients with MDR-TB in resource-
rich settings (the traditional sites for 
randomized trials), clinical trials would 
be extremely difﬁcult to carry out.
How to Resolve the Impasse
Recent developments in MDR-TB 
epidemiology, treatment programs, 
clinical trials methodology, and TB 
drug development suggest an end 
to the present impasse. First, the 
magnitude of the MDR-TB problem is 
now understood to be much greater 
than previously thought. Half a million 
new cases and an additional 1–1.5 
million prevalent cases of MDR-TB were 
estimated to have occurred globally in 
2004 [23]. We also now know that ﬁtness 
costs are not an inevitable consequence 
of mutations that confer resistance 
[24]. And models have illustrated the 
potential epidemiologic importance 
of even a few highly ﬁt, drug-resistant 
strains of M. tuberculosis [25]. There is 
growing consensus that universal access 
to high-quality treatment for all patients 
with TB, including those infected with 
drug-resistant isolates, is the right of 
every patient and is sound public health 
practice [20,26].
Second, MDR-TB treatment 
programs have expanded dramatically: 
40 programs in resource-limited 
settings are managing treatment for 
nearly 30,000 patients. These programs 
receive quality-assured second-line 
drugs through a pooled-procurement 
mechanism supported by the Green 
Light Committee for Access to 
Second-line Antituberculosis Drugs 
(see http://www.who.int/tb/dots/
dotsplus/management_old/en/index.
html) and the Global Fund to ﬁght 
AIDS, Tuberculosis and Malaria. The 
requirements for approval by the 
Green Light Committee have markedly 
raised standards for MDR-TB treatment 
in resource-constrained settings. Some 
of these treatment programs have 
been operating for nearly 10 years 
and have developed sophisticated 
means of delivering supervised 
ambulatory treatment, guided by 
drug susceptibility testing—or drug 
resistance surveys—and other patient-
speciﬁc characteristics. Although few of 
these sites have participated in clinical 
trials, their current standard of care 
could be raised to that certiﬁable as 
“good clinical practice” with limited 
additional investment.
Third, a clinical trial design has been 
developed that allows individualization 
of regimens while evaluating 
rigorously the safety and activity of a 
new drug. According to this design, 
implemented in trials of treatment 
of drug-resistant HIV infection, 
patients receive regimens tailored 
to drug-susceptibility test results and 
individual characteristics. Patients 
are randomized to receive either the 
new drug in addition to the optimized 
background regimen, or the optimized 
background regimen alone. As long 
as randomization is successful in 
distributing key potential confounding 
factors equally between study arms, 
this methodology allows inclusion 
of patients heterogeneous in many 
characteristics: prior drug exposure, 
drug resistance proﬁle, geography, 
ethnicity, and disease stage. A similar 
comparative trial design has been 
used successfully for the pivotal trials 
showing superiority of the last four 
antiretroviral drugs approved in the 
United States (enfuvirtide, tipranavir, 
darunavir, and maraviroc) [27,28].
Fourth, there are several new classes 
of antituberculosis drugs in early 
clinical trials and more in preclinical 
development [29]. Several agents, 
which have been used off-label for 
highly drug-resistant TB in countries 
with established market economies, 
As new drugs with antituberculosis 
activity have been identiﬁed, they 
have been incorporated into MDR-
TB treatment regimens. The use of 
ﬂuoroquinolones for MDR-TB treatment 
exempliﬁes the problems of changing 
therapy in the absence of evidence from 
rigorously conducted clinical trials. The 
ﬂuoroquinolones are considered to be 
the most important drug class in the 
treatment of MDR-TB, based on their in 
vitro activity and favorable results in case 
series.
However, there is agreement neither 
on the best ﬂuoroquinolone for TB 
treatment nor on the optimal duration 
of ﬂuoroquinolone-containing MDR-
TB treatment regimens. The current 
recommended duration of treatment for 
MDR-TB (18–24 months) derives from the 
pre-ﬂuoroquinolone era. In light of the 
excellent activity of the ﬂuoroquinolones, 
it is conceivable that their inclusion 
could shorten treatment for MDR-TB; 
inclusion of class members with greater 
antituberculosis activity could shorten 
treatment further. 
In the absence of data from controlled 
trials and in the face of such high stakes, 
however, clinicians are understandably 
reluctant to shorten ﬂuoroquinolone-
containing MDR-TB regimens. Without 
evidence from clinical trials to show 
the beneﬁts of more active—and more 
expensive—ﬂuoroquinolones in MDR-TB 
regimens, cost considerations alone have 
precluded the use of these newer agents.
Without clinical trials, new agents with 
demonstrable activity will be used for 
MDR-TB treatment. Persistent questions 
about their efﬁcacy, dosing, and toxicity, 
however, will lead to even greater 
heterogeneity in treatment practices—
hardly the way to expand evidence-
based MDR-TB treatment programs 
around the globe.
Box 1: Fluoroquinolones: A Highly Active Drug Class with No 
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could improve MDR-TB treatment 
efﬁcacy in resource-constrained settings 
as well [30–32]. The new drug classes 
have new mechanisms of action. 
Some also have a narrow spectrum of 
activity, speciﬁc only to M. tuberculosis.
Therefore, their activity is not limited by 
the presence of resistance to currently 
available drugs and resistance is unlikely 
to develop through use for other 
indications. Consequently, they hold 
great promise for MDR-TB treatment.
What Is Needed to Move Forward?
Four elements are needed to make 
MDR-TB treatment trials a reality: 
money; additional work on the drug 
pipeline; rigorous, interdisciplinary 
preclinical work on individual agents 
and regimens; and an understanding 
that TB clinical trials need not be a 
zero–sum endeavor (Box 2).
Despite the frequency of MDR-TB, it 
is doubtful that a new drug for MDR-
TB treatment can repay the cost of its 
development. Therefore, resources 
from public institutions, foundations, 
and public–private partnerships are 
required to fund clinical trials for 
MDR-TB. The lack of resources for 
MDR-TB clinical trials is a reﬂection 
of the larger deﬁcit in the ﬁeld of TB 
research. Recent estimates indicate that 
research funding must increase 5-fold 
in order to meet the targets set by the 
Global Plan to Stop TB [33].
The new drugs currently in 
development display promising activity, 
but a substantial attrition rate is 
predicted [34]. Therefore funding for 
basic science, preclinical development, 
and related research should be 
increased. Moreover, this work must be 
integrated with simultaneous efforts to 
implement clinical trials of currently 
available drugs. Since clinical trials are 
expensive, it is critical that new drugs 
and combinations for MDR-TB be fully 
evaluated in a preclinical predictor of 
their efﬁcacy in humans—the animal 
model of TB treatment. Despite 
differences in pharmacokinetics 
and histopathology from human 
tuberculosis, the mouse model can help 
to identify promising doses, dosing 
frequencies, and drug combinations 
for further evaluation in human trials. 
Closer collaboration among other, 
related disciplines (such as medicinal 
chemistry, microbiology, statistics, and 
epidemiology) will further enhance 
drug development efforts.
The ﬁnal element necessary for 
clinical trials of MDR-TB treatment 
is acceptance of the importance of a 
parallel track to evaluate new drugs for 
drug-resistant TB. The focus of recent 
and planned TB clinical trials has been 
the identiﬁcation of shorter regimens 
for drug-susceptible TB. The beneﬁt of 
such regimens would accrue to tens of 
millions sick with TB, by both curing 
extant disease and averting acquisition 
of additional resistance. Consequently, 
concerns have been raised that 
evaluating new drugs for MDR-TB 
may divert scarce resources from the 
development of shorter regimens for 
drug-susceptible TB.
This concern echoes similar 
apprehensions that treating MDR-TB 
in resource-poor settings would divert 
the limited resources of national TB 
control programs and thereby detract 
from TB control [35]. But just as 
MDR-TB treatment in resource-limited 
The following elements are essential 
to ensure the development of optimized 
regimens, which can be widely 
implemented, for the treatment of MDR-
TB.
u Increased funding: 30% of the overall 
estimated 2005 global TB research 
allocation, or $120 million, was 
devoted to drug development [33]. 
The Global Plan to Stop TB, which was 
published prior to the alarming reports 
of XDR-TB, estimated a $4.2 billion gap 
in drug development resources over 
10 years [20]. A recent addendum to 
the Global Plan, the Global MDR-TB 
and XDR-TB Response Plan estimates 
a staggering two-year gap of US$334 
million for R&D related to MDR-TB and 
XDR-TB [37].
u Additional work on the drug 
pipeline: A substantial portion of drug 
development resources is devoted to 
human trials of compounds well into 
the development process. These trials 
have focused mostly on shortening 
ﬁrst-line therapy. Although this is a 
critical goal, with expected beneﬁts in 
reducing the incidence of MDR-TB and 
XDR-TB, its achievement will have no 
impact on the treatment of prevalent 
cases. The likelihood that even one of 
the new compounds currently under 
development will reach the market 
by 2010 has been estimated at less 
than 5% [34]. Efforts in basic science, 
lead-compound optimization, and 
early drug discovery will have to be 
intensiﬁed radically to broaden the 
range of drug targets and to increase 
the probability and efﬁciency of new 
agents reaching the market. Estimated 
at a paltry $68 million in 2005 [33], 
additional investment in basic research 
and drug discovery is essential 
to ensure that new drugs—and 
regimens—become a reality.
u Integration of efforts: A successful 
MDR-TB treatment trials approach 
requires close collaboration along a 
broad spectrum of disciplines, from 
basic research to clinical trials. Close 
interactions between medicinal 
chemists and microbiologists can 
accelerate the optimization of an 
initial compound having promising 
activity. Similarly, better integration 
of animal research and human trials 
will likely result in more efﬁcient 
development; it is essential to resolve 
in animals the questions that are 
most appropriate for that model 
and to reserve questions that can 
be answered only in humans for the 
more expensive, longer clinical trials. 
In each of these models, it will also 
be important to integrate testing 
of new compounds with existing 
agents used for treatment of resistant 
TB. Results from these efforts will 
inform design of parallel trials of new 
agents in drug-susceptible and drug-
resistant TB. Lastly, clinical research 
must incorporate efforts to identify 
and validate surrogate endpoints or 
interim indicators, which will have 
implications for sample size, duration, 
and cost of human trials.
u An understanding that MDR-TB 
clinical trials need not be a zero-sum 
endeavor: Optimization of MDR-TB 
treatment is essential to fulﬁll the 
promise of universal access to effective 
treatment for all patients with TB. The 
HIV model has shown that substantial 
beneﬁts may accrue to acceleration of 
regulatory approval of antituberculosis 
agents through development 
of a parallel track of testing 
antituberculosis agents in patients 
with resistant disease. An aggressive 
MDR-TB clinical trials agenda can also 
enhance overall support for TB control.
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settings can boost TB control [36], 
clinical trials of new drugs for MDR-TB 
treatment can enhance and accelerate 
drug development efforts.
The threats of MDR- and XDR-
TB, moreover, may prove to be a 
key element in mobilizing increased 
funding for all TB drug development; 
their prevalence will undoubtedly grow 
if improved therapy is not made widely 
available. And the ﬁnancial and human 
costs will be even higher. Furthermore, 
the activity of a new drug may be more 
easily observed in the context of the 
relatively weak companion drugs used 
in MDR-TB treatment than in the 
presence of other potent drugs used for 
drug-susceptible disease. Differences 
in treatment response, which are more 
easily detected in MDR-TB therapy, 
would allow smaller and shorter clinical 
trials. As in HIV, clinical trials in 
patients with drug-resistant disease may 
provide a quicker and less expensive 
path to licensure than demonstrating 
that a new drug can substantially 
improve the treatment for drug-
susceptible disease.
The Time Is Now
The devastating outbreak of XDR-TB 
in KwaZulu-Natal [4] is a reminder 
of the threat MDR-TB represents 
to individuals and to global public 
health. A continued failure to make 
appropriate therapy for MDR/XDR-TB 
widely available is unacceptable, as it 
will have a profoundly negative impact 
on global TB control.
In recent years, the landscape of 
TB control has changed dramatically. 
It is now possible to employ a bold, 
integrated approach in responding 
to such outbreaks and averting their 
spread. The time is right for clinical 
trials of MDR-TB therapy: existing 
treatment programs throughout the 
world can form the backbone for a 
clinical trials effort; new drug classes 
are entering clinical trials; and we now 
have a ﬂexible trial design that allows 
individualization of therapy while 
preserving a rigorous randomized 
evaluation of the safety and efﬁcacy of 
a new agent. New, optimized regimens 
that will be identiﬁed in clinical 
trials can be quickly integrated into 
routine program practice through the 
expanding global network of MDR-
TB treatment programs. Signaling 
the changing times, at least two 
pharmaceutical companies, Tibotec 
and Otsuka, have publicly announced 
plans to evaluate a new drug in patients 
with MDR-TB. We have an ambitious 
goal and responsibility—to successfully 
treat nearly 1.6 million MDR-TB 
patients by 2015—and clinical trials 
to identify safer and more effective 
treatment are a key to fulﬁlling that 
goal. The time for action is now.  
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